USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Glaxosmithkline Intellectual Property Development Limited

USPTO PatentsView assignee record - 214 granted patents across 37 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

214

Total patents granted

CPC technology areas

15.9

Avg claims per patent

+18%

5-year filing velocity

The verdict

Glaxosmithkline holds 214 US patents across 37 technology areas, rank #1,874 of 50,000 tracked assignees.

#1,874
of 50,000 US assignees by volume: Top 10%
by Innovation Score (52.7/100): 15.9
avg claims per patent: +18%
filing velocity, last 5 yrs

Portfolio overview

Glaxosmithkline Intellectual Property Development Limited has been granted 214 US utility patents between 2015 and 2025, placing Glaxosmithkline Intellectual Property Development Limited at rank #1,874 across all assignees tracked by PlainPatent. This portfolio spans 37 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Glaxosmithkline Intellectual Property Development Limited is one of the more focused assignees in the PatentsView dataset. By volume, Glaxosmithkline sits between Zoetis Services Llc (215 patents, rank #1,870) and Minebea Co., Ltd. (214 patents, rank #1,878) - the closest US assignees by grant volume. The composite Innovation Score of 52.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 116 grants, compared with 98 in the 2015–2019 window, a +18% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Glaxosmithkline Intellectual Property Development Limited's 15.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 37 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Glaxosmithkline Intellectual Property Development Limited against peers pursuing similar technology classes.

Zoetis Services

215
AWI Licensing

214
Darfon

214
F5 Networks

214
Grundfos Holding…

214
Johnson Electric…

214
MKS Instruments

214
Minebea

214
Glaxosmithkline I… ◀

214

What this shows Glaxosmithkline holds 214 patents at rank #1,874, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Glaxosmithkline

By rank, the assignees closest to #1,874 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Glaxosmithkline's primary technology class.

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

53 Top 10% higher than 90% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Glaxosmithkline Intellectual Property Development Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	3.3%
2016	5	2.3%
2017	21	9.8%
2018	28	13.1%
2019	37	17.3%
2020	31	14.5%
2021	29	13.6%
2022	20	9.3%
2023	14	6.5%
2024	11	5.1%
2025	11	5.1%

Which technologies does Glaxosmithkline Intellectual Property Development Limited patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 180

C07D - HETEROCYCLIC COMPOUNDS 151

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 112

C07K - PEPTIDES 37

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 20

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 15

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 12

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 12

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 11

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 10

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 8

C12Y - ENZYMES 5

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 3

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 3

B01L - CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE 2

Top 15 of 37 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#1,874

Across all tracked assignees

Innovation Score

52.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Glaxosmithkline Intellectual Property Development Limited hold?

Glaxosmithkline Intellectual Property Development Limited holds 214 US granted patents filed between 2015 and 2025, spanning 37 technology areas.

What is Glaxosmithkline Intellectual Property Development Limited's Innovation Score?

Glaxosmithkline Intellectual Property Development Limited has an Innovation Score of 52.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Glaxosmithkline Intellectual Property Development Limited focus on?

Glaxosmithkline Intellectual Property Development Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 180 patents. The company has filed patents in 37 CPC subclasses total.

Is Glaxosmithkline Intellectual Property Development Limited's patent filing rate increasing or decreasing?

Glaxosmithkline Intellectual Property Development Limited's recent filing velocity is +18% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Glaxosmithkline Intellectual Property Development Limited's patents?

Glaxosmithkline Intellectual Property Development Limited's patents average 15.9 claims each. This falls within the standard range, providing solid legal coverage.

How is the Glaxosmithkline Intellectual Property Development Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Glaxosmithkline's 214 grants land it in the top 10% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Glaxosmithkline ranks #1,874 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.